Renovaro Inc. Files 8-K/A Amendment

TL;DR

Renovaro Inc. amended its Feb 9th filing on April 24th, adding financial statements and exhibits.

AI Summary

Renovaro Inc. filed an amendment (8-K/A) on April 24, 2024, to a report originally dated February 9, 2024. This amendment pertains to financial statements and exhibits. The company, formerly known as Enochian Biosciences Inc. and Renovaro Biosciences Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information, which could be material for investors tracking the company's financial and exhibit disclosures.

Risk Assessment

Risk Level: low — This is a procedural amendment to a previous filing, not a new event or significant financial disclosure.

Key Players & Entities

• Renovaro Inc. (company) — Registrant
• Enochian Biosciences Inc. (company) — Former company name
• Renovaro Biosciences Inc. (company) — Former company name
• February 9, 2024 (date) — Original report date
• April 24, 2024 (date) — Filing date of amendment

FAQ

Key Financial Figures

• $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar

Filing Documents

• e5613_8-ka.htm (8-K/A) — 31KB
• e5613_ex23-1.htm (EX-23.1) — 2KB
• e5613_ex99-1.htm (EX-99.1) — 215KB
• e5613_ex99-2.htm (EX-99.2) — 137KB
• 0001731122-24-000681.txt ( ) — 602KB
• renb-20240209.xsd (EX-101.SCH) — 3KB
• renb-20240209_lab.xml (EX-101.LAB) — 33KB
• renb-20240209_pre.xml (EX-101.PRE) — 22KB
• e5613_8-ka_htm.xml (XML) — 4KB

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (a) Financial Statements of Business Acquired The consolidated financial statements of Renovaro Cube as of December 31, 2023 and 2022 and the related consolidated balance sheets, statements of operations, consolidate statements of changes in stockholders' deficit and consolidated statements of cash flows for the period from January 1, 2023 to August 23, 2023, period from August 24, 2023 to December 31, 2023, and for the year ended December 31, 2022, together with the accompanying notes thereto are filed as Exhibit 99.1 hereto and are incorporated herein by reference. (b) Pro Forma Financial Information The unaudited pro forma condensed combined financial statements of the Company for the six-month period ended December 31, 2023 is filed as Exhibit 99.2 and incorporated by reference herein. (d) Exhibits. EXHIBIT NO. DESCRIPTION LOCATION 23.1 Consent of Sadler, Gibb & Associates Filed herewith 99.1 Audited financial statements of Renovaro Cube Intl Ltd. as of and for the years ended December 31, 2023 and 2022. Filed herewith 99.2 Unaudited Pro Forma Condensed Combined Balance Sheet as of December 31, 2023, Unaudited Pro Forma Condensed Combined Statements of Operations for the six months ended December 31, 2023 and the year ended June 30, 2023 Filed herewith 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO INC. By: /s/ Mark Dybul, M.D. Name: Mark Dybul Title: Chief Executive Officer Date: April 24, 2024

View Full Filing

View this 8-K/A filing on SEC EDGAR